Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy
暂无分享,去创建一个
Masanori Nakagawa | Masaya Ikegawa | Herbert Thiele | Takashi Kasai | Takahiko Tokuda | Takashi Nirasawa | Kei Tashiro | T. Tokuda | M. Nakagawa | K. Tashiro | T. Kondo | H. Thiele | Y. Matsuyama | Takayuki Kondo | T. Nirasawa | M. Komori | Mika Komori | Noriko Ishigami | Yumiko Matsuyama | M. Ikegawa | T. Kasai | N. Ishigami
[1] G. Wenning,et al. Multiple system atrophy: an update , 2009, The Lancet Neurology.
[2] Ralf Ketterlinus,et al. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. , 2005, BioTechniques.
[3] T. Tokuda,et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .
[4] W. F. Abdo,et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[5] K. Tashiro,et al. Applying Magnetic Bead Separation / MALDI-TOF Mass Spectrometry to Human Tear Fluid Proteome Analysis , 2008 .
[6] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[7] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[8] Aneeka M Hancock,et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.
[9] J. Kassubek,et al. Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.
[10] T. Tokuda,et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.
[11] Klaus Seppi,et al. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.
[12] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[13] Stefano Ferrero,et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt , 2008, Proteomics. Clinical applications.
[14] 小森 美華,et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders , 2012 .
[15] K. Helle. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects , 2004, Biological reviews of the Cambridge Philosophical Society.
[16] K. Blennow,et al. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. , 2010, Parkinsonism & related disorders.
[17] Yu Wang,et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.
[18] P Sandroni,et al. Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.
[19] Gordana Ivosev,et al. Dimensionality reduction and visualization in principal component analysis. , 2008, Analytical chemistry.
[20] Jing Zhang,et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.
[21] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[22] Yan Liu,et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.
[23] H. Groenewegen,et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach , 2010, Neurobiology of Disease.